{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:06:28Z","timestamp":1791234388795,"version":"4.1.0"},"reference-count":44,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2013,10,26]]},"published-print":{"date-parts":[[2014,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>Acid-suppressive medications, particularly proton pump inhibitors (PPIs), may decrease the risk of oesophageal adenocarcinoma (OAC) in patients with Barrett's oesophagus (BO). We performed a systematic review with meta-analysis of studies evaluating the association between acid-suppressive medications (PPIs and histamine receptor antagonists (H2RAs)) and risk of OAC or high-grade dysplasia (BO-HGD) in patients with BO.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a systematic search of multiple electronic databases and conference proceedings up to June 2013 to identify studies reporting the association between use of acid-suppressive medications and risk of OAC and\/or BO-HGD in patients with BO. Summary ORs with 95% CIs were estimated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified seven observational studies (2813 patients with BO, 317 cases of OAC or BO-HGD, 84.4% PPI users). On meta-analysis, PPI use was associated with a 71% reduction in risk of OAC and\/or BO-HGD in patients with BO (adjusted OR 0.29; 95% CI 0.12 to 0.79). There was a trend towards a dose\u2013response relationship with PPI use for &gt;2\u20133\u2005years protective against OAC or BO-HGD (three studies; PPI use &gt;2\u20133\u2005years vs &lt;2\u20133\u2005years: OR 0.45 (95% CI 0.19 to 1.06) vs 1.09 (0.47 to 2.56)). Considerable heterogeneity was observed. Two studies reported the association between H2RA use and risk of OAC and\/or BO-HGD (1352 patients with BO, 156 cases of OAC, 25.4% on H2RAs), and both studies did not show a significant effect.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Based on meta-analysis of observational studies, the use of PPIs is associated with a decreased risk of OAC and\/or BO-HGD in patients with BO. None of the studies showed an increased risk of OAC. PPI use should be considered in BO, and chemopreventive trials of PPIs in patients with BO are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/gutjnl-2013-305997","type":"journal-article","created":{"date-parts":[[2013,11,12]],"date-time":"2013-11-12T22:58:29Z","timestamp":1384297109000},"page":"1229-1237","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":254,"title":["Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis"],"prefix":"10.1136","volume":"63","author":[{"given":"Siddharth","family":"Singh","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushil Kumar","family":"Garg","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Minnesota, Minneapolis, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preet Paul","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasad G","family":"Iyer","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hashem B","family":"El-Serag","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2013,11,12]]},"reference":[{"key":"2025120518523076000_63.8.1229.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21185"},{"key":"2025120518523076000_63.8.1229.2","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1053\/j.gastro.2011.01.031","article-title":"American Gastroenterological Association technical review on the management of Barrett's esophagus","volume":"140","author":"Spechler","year":"2011","journal-title":"Gastroenterology"},{"key":"2025120518523076000_63.8.1229.3","doi-asserted-by":"publisher","DOI":"10.1038\/ncpgasthep0412"},{"key":"2025120518523076000_63.8.1229.4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2008.02129.x"},{"key":"2025120518523076000_63.8.1229.5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2008.02117.x"},{"key":"2025120518523076000_63.8.1229.6","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.06.044"},{"key":"2025120518523076000_63.8.1229.7","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.00939.x"},{"key":"2025120518523076000_63.8.1229.8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0015"},{"key":"2025120518523076000_63.8.1229.9","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.086579"},{"key":"2025120518523076000_63.8.1229.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.11.014"},{"key":"2025120518523076000_63.8.1229.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.06.001"},{"key":"2025120518523076000_63.8.1229.12","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-4-200908180-00135"},{"key":"2025120518523076000_63.8.1229.13","unstructured":"Wells GA Shea B O'Connell D . The Newcastle\u2013Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp (accessed 31 Oct 2013)"},{"key":"2025120518523076000_63.8.1229.14","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"2025120518523076000_63.8.1229.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2011.03.017"},{"key":"2025120518523076000_63.8.1229.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.09.019"},{"key":"2025120518523076000_63.8.1229.17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.323.7304.101"},{"key":"2025120518523076000_63.8.1229.18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00626.x"},{"key":"2025120518523076000_63.8.1229.19","doi-asserted-by":"crossref","first-page":"387","DOI":"10.5694\/j.1326-5377.2004.tb05991.x","article-title":"Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus","volume":"180","author":"Hillman","year":"2004","journal-title":"Med J Aust"},{"key":"2025120518523076000_63.8.1229.20","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.02.045"},{"key":"2025120518523076000_63.8.1229.21","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.14309\/00000434-201110002-00074","article-title":"Can progression to dysplasia in Barrett's esophagus be prevented by proton pump inhibitors?","volume":"106","author":"Altawil","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"2025120518523076000_63.8.1229.22","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.130"},{"key":"2025120518523076000_63.8.1229.23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2004.30228.x"},{"key":"2025120518523076000_63.8.1229.24","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.153"},{"key":"2025120518523076000_63.8.1229.25","doi-asserted-by":"crossref","first-page":"S258","DOI":"10.1016\/S0016-5085(11)61033-0","article-title":"Chemoprevention of Barrett's esophagus in patients with acid reflux","volume":"140","author":"Altawil","year":"2011","journal-title":"Gastroenterology"},{"key":"2025120518523076000_63.8.1229.26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2050.2008.00886.x"},{"key":"2025120518523076000_63.8.1229.27","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1365-2036.2007.03579.x","article-title":"Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus","volume":"27","author":"Hillman","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"2025120518523076000_63.8.1229.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.10.010"},{"key":"2025120518523076000_63.8.1229.29","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.06.055"},{"key":"2025120518523076000_63.8.1229.30","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.369"},{"key":"2025120518523076000_63.8.1229.31","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.11.019"},{"key":"2025120518523076000_63.8.1229.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.12.036"},{"key":"2025120518523076000_63.8.1229.33","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.041558"},{"key":"2025120518523076000_63.8.1229.34","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(00)70254-X"},{"key":"2025120518523076000_63.8.1229.35","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1312922"},{"key":"2025120518523076000_63.8.1229.36","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1999.0029900327"},{"key":"2025120518523076000_63.8.1229.37","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-009-0951-9"},{"key":"2025120518523076000_63.8.1229.38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.02825.x"},{"key":"2025120518523076000_63.8.1229.39","doi-asserted-by":"crossref","first-page":"S219","DOI":"10.1016\/S0016-5085(11)60886-X","article-title":"Effect of proton pump inhibitors (PPIs) treatment on the length of Barrett's esophagus: a systematic review of cohort studies","volume":"140","author":"Win","year":"2011","journal-title":"Gastroenterology"},{"key":"2025120518523076000_63.8.1229.40","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2003.50091"},{"key":"2025120518523076000_63.8.1229.41","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2009.191403"},{"key":"2025120518523076000_63.8.1229.42","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2009.186775"},{"key":"2025120518523076000_63.8.1229.43","doi-asserted-by":"crossref","first-page":"S204","DOI":"10.1016\/S0016-5085(11)60826-3","article-title":"Cost-effectiveness of chemoprevention with and without proton pump inhibitors in Barrett's esophagus","volume":"140","author":"Sharaiha","year":"2011","journal-title":"Gastroenterology"},{"key":"2025120518523076000_63.8.1229.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2009.04.014"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2013-305997","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T02:52:37Z","timestamp":1764989557000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2013-305997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,12]]},"references-count":44,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2014,7,8]]},"published-print":{"date-parts":[[2014,8]]}},"alternative-id":["10.1136\/gutjnl-2013-305997"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2013-305997","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,12]]}}}